[O-46] 一般演題口演セッション46 治療創薬、再生医療3

[O-46-5] ENVISION試験非盲検継続投与18ヶ月時点でのGivosiranの有効性と安全性

^○足立 智英¹, David Kuter², Siobán Keel³, Charles Parker⁴, David C. Rees⁵, Ulrich Stölzel⁶, Paolo Ventura⁷, Manisha Balwani⁸, Laurent Gouya⁹, Amy Simon¹⁰, Shangbin Liu¹⁰, John Ko¹⁰, Sean Rhyee¹⁰, Samuel Silver¹¹ (1.東京都済生会中央病院 脳神経内科・総合診療内科, 2.Massachusetts General Hospital, Boston, Massachusetts, USA, 3.University of Washington, Seattle, Washington, USA, 4.University of Utah, Salt Lake City, Utah, USA, 5.King’s College Hospital, United Kingdom, 6.Klinikum Chemnitz, Chemnitz, Germany, 7.Università degli Studi di Modena e Reggio Emilia, Modena, Italy, 8.Icahn School of Medicine at Mt. Sinai, New York, New York, USA, 9.Centre Français des Porphyries, Paris, France, 10.Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA, 11.University of Michigan, Ann Arbor, Michigan, USA)